Ad-hoc | 10 October 2005 21:32

Biotest AG: Biotest fixes subscription price

Ad hoc announcement §15 WpHG Measures in relation to changes in capital Biotest AG: Biotest fixes subscription price Ad hoc announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. —————————————————————————— Ad hoc announcement pursuant to § 15 German Securities Trading Act (Wertpapierhandelsgesetz – WpHG) Measures in relation to changes in capital Biotest AG: Biotest fixes a subscription price of EUR 22.50 per ordinary share and EUR 18.50 per preference share Dreieich, 10 October 2005. With the approval of the supervisory board, the management board of Biotest AG has fixed the subscription price for the company’s new shares issued within the framework of a capital increase. The ordinary shareholders of Biotest AG will be offered 856,525 newly issued shares at a subscription price of EUR 22.50 per share and the preference shareholders will be offered 666,667 preference shares at a subscription price of EUR 18.50 per share. In relation to the volume weighted average price over the last 30 trading days, this equals to a calculative 14.8 per cent reduction for ordinary shares and of 15.4 per cent reduction for preference shares. The shareholders are entitled to a statutory right of subscription. Any subscription right of the ordinary shareholders to subscribe to preference shares and any subscription right of the preference shareholders to subscribe to ordinary shares is excluded. In order to settle any fractional amount, the right to subscribe to one preference share is excluded. The subscription ratio is 6:1, in each case. For the year 2005, the new shares are fully entitled to dividend payments. The underwriting banks Commerzbank Aktiengesellschaft, Frankfurt am Main, Landesbank Baden-Württemberg, Stuttgart, and equinet Securities AG Wertpapierhandelsbank, Frankfurt am Main, acquired the new ordinary and preference shares together with the obligation to offer these shares to the ordinary and preference shareholders of Biotest for subscription. The offer for subscription will be published on 13 October 2005 in the electronic Federal Gazette (Bundesanzeiger) and on the company’s internet pages (www.biotest.de). (Commencement of trading of subscription rights and subscription period). The trading of subscription rights will end on 25 October, the subscription period will end on 27 October 2005. The listing of the new shares is scheduled for 31 October 2005. In the event of the complete placement of shares, the capital increase will result in net issuing proceeds of approximately EUR 30 million. Biotest plans to invest this amount in research and development projects and the expansion of its international sales organization, amongst other things. Investor Relations: Hubert Bötsch, Telephone: +49 (0) 6103 801-444, Telefax: +49 (0) 6103 801-880, E-mail: hubert_boetsch@biotest.de Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de Biotest AG Landsteinerstraße 5 63303 Dreieich Deutschland ISIN: DE0005227201; DE0005227235 WKN: 522720; 522723 Listed: Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg und Stuttgart End of ad hoc announcement (c)DGAP 10.10.2005 102132 Okt 05